MRKR

NASDAQ 已收盘

Marker Therapeutics

1.09 USD
▼-0.23-17.42%
盘后 1.05 -3.67%
2026-11-20
市值
$18.17M
市盈率
—
EPS
-0.44
股息率
—
52 周区间
0.81 – 2.46
成交量
1.97M
Beta
1.62
目标价
7.87
52W 低 0.8152W 高 2.46
价格走势

公司简介

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreat...